Evidence map›Paper›PMID 38380861›Full record

Trial reportLeukemia & lymphoma2024

Effect of atorvastatin versus placebo on efficacy in patients with diffuse large B-cell lymphoma receiving R-CHOP.

Ronald Nemec, Marielle Scherrer-Crosbie, Jeremy S Abramson, Robert Redd, Hannah K Gilman, Terry Ho, Jessica Wu, Julius Heemelaar, Donna Neuberg, Ephraim P Hochberg and 9 more

Abstract readRandomized Controlled TrialMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Leukemia & lymphoma, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Ronald NemecCenter for Lymphoma, Massachusetts General Hospital Cancer Center, Boston, MA, USA.
Marielle Scherrer-CrosbieDivision of Cardiology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.
Jeremy S AbramsonCenter for Lymphoma, Massachusetts General Hospital Cancer Center, Boston, MA, USA.
Robert ReddDepartment of Data Science, Dana Farber Cancer Institute, Boston, MA, USA.
Hannah K GilmanDivision of Cardiology, Massachusetts General Hospital, Boston, MA, USA.
Terry HoDivision of Cardiology, Massachusetts General Hospital, Boston, MA, USA.
Jessica WuDivision of Cardiology, Massachusetts General Hospital, Boston, MA, USA.
Julius HeemelaarDivision of Cardiology, Massachusetts General Hospital, Boston, MA, USA.
Donna NeubergDepartment of Data Science, Dana Farber Cancer Institute, Boston, MA, USA.
Ephraim P HochbergCenter for Lymphoma, Massachusetts General Hospital Cancer Center, Boston, MA, USA.
Jeffrey A BarnesCenter for Lymphoma, Massachusetts General Hospital Cancer Center, Boston, MA, USA.
Philippe ArmandDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Eric D JacobsenDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Caron A JacobsonDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Austin I KimDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Robb S FriedmanDivision of Medical Oncology, Newton-Wellesley Hospital, Newton, MA, USA.
Ann S LaCasceDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Tomas G NeilanDivision of Cardiology, Massachusetts General Hospital, Boston, MA, USA.
Jacob D SoumeraiCenter for Lymphoma, Massachusetts General Hospital Cancer Center, Boston, MA, USA.ORCID 0000-0002-3062-6819

Funding

Predictive markers for personalized therapy in chronic lymphocytic leukemiaK08CA270202 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI Jacob Soumerai · 2023 to 2026
$1.1M
NCI NIH HHS K08 CA270202
6 · The paper itself

Abstract

STOP-CA was a multicenter, double-blind, randomized, placebo-controlled trial comparing atorvastatin to placebo in treatment-naïve lymphoma patients receiving anthracycline-based chemotherapy. We performed a preplanned subgroup to analyze the impact of atorvastatin on efficacy in patients with diffuse large B-cell lymphoma (DLBCL). Patients received rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) at standard doses for six 21-day cycles and were randomly assigned to receive atorvastatin 40 mg daily (

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsAtorvastatinCyclophosphamideDoxorubicinLymphoma, Large B-Cell, DiffusePrednisoneRituximabVincristineAdultAgedDouble-Blind MethodFemaleHumansMaleMiddle AgedTreatment OutcomeAtorvastatinCyclophosphamideDoxorubicinPrednisoneR-CHOP protocolRituximabVincristineanthracyclineAtorvastatindiffuse large B-cell lymphomaR-CHOP

Identifiers

PMID38380861
PMCPMC11342236

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.